Oncorus, Inc. - ONCR STOCK NEWS

Oncorus reported a net loss of $19.1 million, or $0.74 per share, for Q2 2022, compared to a loss of $15.5 million, or $0.60 per share, in Q2 2021. Cash and cash equivalents stood at $100.2 million as of June 30, 2022. The company continues to enroll patients in the ONCR-177 Phase 1 trial and plans to submit an IND for ONCR-021 by mid-2023. Notable developments include a debt agreement with K2 HealthVentures for up to $45 million and plans to relocate operations to enhance efficiency. Initial data from clinical trials is expected in H2 2022.

Oncorus, Inc. has appointed Douglas M. Fambrough, III, Ph.D. to its board of directors, enhancing its expertise in RNA research and drug development. Dr. Fambrough, former CEO of Dicerna, brings over 25 years of experience in biotechnology, including overseeing Dicerna's success leading to its acquisition by Novo Nordisk for $3.3 billion. His appointment aims to strengthen Oncorus’ next-generation HSV and viral RNA platforms, potentially advancing their pipeline of cancer immunotherapies.

Oncorus, Inc. (Nasdaq: ONCR), a leader in viral immunotherapies, announced that CEO Theodore Ashburn will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 8, 2022, at 3:30 p.m. ET in New York. Investors can access the live webcast through the Investors & Media section of Oncorus' website, with a replay available for 90 days post-event. Oncorus is focused on innovative viral immunotherapies targeting cancer, with leading programs including ONCR-177, ONCR-021, and ONCR-788, aimed at enhancing therapeutic effectiveness while minimizing toxicity.

Oncorus, Inc. (Nasdaq: ONCR) announced that its CEO, Theodore Ashburn, will present an update on the company's advancements at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. ET. The presentation will be accessible for on-demand viewing on Oncorus' website. This company focuses on developing innovative viral immunotherapies to improve cancer patient outcomes, utilizing their proprietary platforms, including ONCR-177, ONCR-021, and ONCR-788, aimed at addressing significant unmet medical needs in cancer therapy.

Oncorus, Inc. (Nasdaq: ONCR) announced the appointment of Richard Wanstall as Chief Financial Officer, bringing over 25 years of experience in biotech finance. CEO Ted Ashburn expressed confidence in Wanstall's ability to guide Oncorus through its growth phase, particularly with key clinical trials underway for ONCR-177 and ONCR-021. The company is positioned for significant advancements in cancer immunotherapy with ongoing trials and a cash runway extending into early 2024. Wanstall's leadership is expected to enhance financial strategy and operations during this critical period.

Oncorus, Inc. (Nasdaq: ONCR) reported its Q1 2022 financial results, highlighting a net loss of $17.8 million, or $0.69 per share. Cash reserves decreased to $98.7 million. The company remains on track to release additional clinical data for ONCR-177 in H2 2022, following successful preclinical results for ONCR-021 and ONCR-788 presented at the AACR Annual Meeting. Oncorus also secured a $45 million debt facility with K2 HealthVentures, enhancing its cash runway into early 2024, alongside plans to relocate operations to a more efficient facility in Andover, Massachusetts.

Oncorus announced promising preclinical data for its vRNA Immunotherapy Platform, specifically the candidates ONCR-021 and ONCR-788, at the AACR Annual Meeting 2022. Both demonstrated significant anti-tumor efficacy following intravenous administration, even in the presence of neutralizing antibodies. ONCR-021 targets non-small cell lung cancer and other tumors, with an IND submission planned for mid-2023, while ONCR-788 is aimed at neuroendocrine tumors, also with an IND expected afterward. The vRNA platform shows potential to overcome challenges faced by existing RNA-based oncology therapies.

Oncorus, Inc. has secured a $45 million debt financing agreement with K2 HealthVentures to enhance its operations. The funds will support the completion of a GMP-compliant manufacturing facility in Andover, MA, and development of its vRNA/LNP product candidate ONCR-021. The initial $20 million tranche has been drawn down. Furthermore, Oncorus plans to relocate its corporate headquarters to Andover by Q4 2022, extending its cash runway into early 2024. This strategic move aims to foster operational efficiency and advance its pipeline of viral immunotherapies.

On March 21, 2022, Oncorus, a leader in viral immunotherapies, announced that its CEO, Theodore Ashburn, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022, at 12:30 p.m. ET. Additionally, Dr. Ashburn will present a corporate overview available for on-demand viewing starting at 9:00 a.m. ET on the same day. The live webcast and on-demand presentation can be accessed on Oncorus’ website until March 30. The company focuses on innovative therapies to improve cancer treatment outcomes.